SGLT2 inhibitors in the treatment of diabetes mellitus

Czech version

Authors: Peter Jackuliak; Magdaléna Kovářová; Juraj Payer
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in: Forum Diab 2020; 9(2): 104-108
Category:

Overview

SGLT2 inhibitors are the latest class of antidiabetic drugs. Initial scepticism about the mechanism of action – glycosuria – was replaced by a strong enthusiasm over the complex cardio metabolic effect of this group of antidiabetic drugs. Inhibitors SGLT2 in the management of a patient with type 2 diabetes mellitus significantly reduces glycemia, without the risk of hypoglycaemia, have a positive effect on blood pressure decrease, improve the heart failure. Cardiovascular oriented trials (CVOT) have shown a significant benefit in reducing cardiovascular mortality and reducing the risk of individual cardiovascular events (stroke, acute coronary syndrome and cardiovascular death). All benefits significantly overweigh the risks of these drugs. According to the latest treatment algorithms is this group in the second-line (in Slovakia for indication constraints in the third-line), preferred for patients with atherosclerotic cardiovascular disease, heart failure and chronic kidney disease.

Keywords:

cardiovascular benefits – type 2 diabetes mellitus – inhibitors SGLT2

Sources

Brown E, Rajeev SP, Cuthbertson DJ et al. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab 2019; 21(Suppl 2): 9–18. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13650>.

Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 2018; 61(10): 2098–2107. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4669–0>.

Zaccardi F, Webb DR, Htike ZZ et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016; 18(8): 783–794. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12670>.

Ferrannini E. Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. Cell Metab 2017; 26(1): 27–38. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2017.04.011>.

Bonner C, Kerr-Conte J, Gmyr V et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015; 21(5): 512–517. Dostupné z DOI: <http://dx.doi.org/10.1038/nm.3828>.

Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124(2): 499–508. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI72227>. Erratum in J Clin Invest. 2014; 124(4): 1868.

Sasaki M, Sasako T, Kubota N et al. Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney. Diabetes 2017; 66(9): 2339–2350. Dostupné z DOI: <http://dx.doi.org/10.2337/db16–1602>.

Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.

Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389

Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.

Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 2018; 61(10): 2118–2125. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4663–6>.

Stenlöf K, Cefalu WT, Kimet KA al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15(4): 372–382. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12054>.

Roden M, Weng J, Eilbrachtet J al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1(3): 208–219. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(13)70084–6>.

Wang Z, Sun J, Hanet R al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab 2018; 20(1): 113–120. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13047>.

Catani Pinto L, Varvaki Rados D, Reck Remonti L et al. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr 2015; 7(Suppl 1): A58. Dostupné z DOI: <http://dx.doi.org/10.1186/1758–5996–7-S1-A58>.

Vasilakou D, Karagiannis T, Athanasiadouet E al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159(4): 262–274. Dostupné z DOI: <http://dx.doi.org/10.7326/0003–4819–159–4-201308200–00007>.

Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med 2017; 376(23): 2300–2302. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMc1701990>.

Watts NB, Bilezikian JP, Usiskin K et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2016; 101(1): 157–166. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2015–3167>.

Tang HL, Li DD, Zhang JJ et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 2016; 18(12): 1199–1206. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12742>.

Majewski C, Bakris GL. Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes. Diabetes Care 2015; 38(3): 429–430. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14–1596>.

Schork A, Saynisch J, Vosseler A et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovascular Diabetology 2019; 18(1): 46. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–019–0852-y>.

Verma S, Mazer CD, Fitchett D et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(R) randomised trial. Diabetologia 2018; 61(8): 1712–1723. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4644–9>.

Fitchett D, Butler J, van de Borne P et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 2018; 39(5): 363–370. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx511>.

Rådholm K, Figtree G, Perkovic V et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation 2018; 138(5): 458–468. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034222>.

Davies MJ, D’Alessio D, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61(12): 2461–2498. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4729–5>.

Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.

Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 2016; 37(42): 3192–3200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw110>.

Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60(2): 215–225. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–016–4157–3>.

Verma S, McMurray JJ, Cherney DZ. The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiol 2017; 2(9): 939–940. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2017.1891>.

Baruah MP, Makkar BM, Ghatnatti VB et al. Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control. Indian J Endocrinol Metab 2019; 23(1): 140–149. Dostupné z DOI: <http://dx.doi.org/10.4103/ijem.IJEM_160_17>.